NVIC

Janssen/Johnson & Johnson COVID-19 Vaccine

Published November 10, 2021

In March 2020, Janssen/Johnson & Johnson announced that it had expanded its partnership with BARDA to reach its goal of providing one billion COVID-19 vaccine doses. Company officials reported that human trials of an experimental COVID-19 vaccine utilizing its AdVac® and PER.C6® technologies would likely begin in September 2020.  The AdVac technology uses an adaptation of human Adenovirus 26 to transport the genetic code of the SARS-CoV-2 spike protein into the body to trigger an immune response.    PER.C6 are proprietary cells owned by Janssen Pharmaceutical that were developed in 1985 from retinal cells of an 18-week-old aborted fetus. 

The Janssen/Johnson & Johnson experimental COVID-19 vaccine entered Phase 2 trials in Spain in mid-September 2020.  Clinical trials, however, were halted on October 12, 2020 after a participant developed an “unexplained illness.”  Sources familiar with the event reported that a male in his 20’s had a stroke after receiving the experimental vaccine.  Clinical trials in the U.S resumed in late October 2020. 

On January 29, 2021, company officials reported that overall, their COVID-19 vaccine was 66 percent effective at preventing moderate to severe symptoms, 85 percent effective at severe illness, and 100 percent effective at preventing COVID-19-related hospitalizations and deaths. 

Janssen/Johnson & Johnson COVID-19 Vaccine EUA

On February 27, 2021, the FDA issued an EUA for Janssen/Johnson & Johnson’s experimental vaccine for use in persons 18 years of age and older.  In clinical trials, the vaccine was reported to be 67 percent effective in preventing moderate to severe COVID-19 occurring at least 14 days after vaccination and 66 percent effective in preventing moderate to severe COVID-19 occurring at least 28 days after vaccination.  The vaccine, however, was reported to be only 42 percent effective in persons over the age of 60 with underlying health conditions. 

Common side effects reported after vaccine administration with the Janssen/Johnson & Johnson COVID-19 vaccine in clinical trials included injection site pain, headache, fatigue, myalgia, nausea, fever, injection site redness and swelling. 

Serious adverse events reported after vaccine administration included severe pain in the injected arm, hives, hypersensitivity, deep vein thrombosis, pulmonary embolism, transverse sinus thrombosis, severe generalized weakness with fever and headache, tinnitus (ringing or buzzing noises in the ears) and seizures. 

On April 13, 2021, the FDA and CDC paused use of the vaccine after serious blood clots were reported in women between the ages of 18 and 49.  By April 23, 2021, 15 cases and 3 deaths had been associated with the rare blood clot disorder, now referred to by health officials as thrombosis with thrombocytopenia syndrome (TTS). All cases were reported in women, with two occurring in women over 50 years of age. The CDC’s ACIP voted to resume full use of the vaccine in all persons 18 years of age and older on April 23, 2021, by a vote of 10 to 4 (with one voting member abstaining due to a conflict of interest). Those who voted against the recommendation expressed concern regarding the lack of warning on the risk of TTS in women under 50 years of age.   

On April 23, 2021, the FDA updated the Janssen/Johnson & Johnson’s COVID-19 Fact Sheet and acknowledged that: 

“Reports of adverse events following use of the Janssen COVID-19 Vaccine under emergency use authorization suggest an increased risk of thrombosis involving the cerebral venous sinuses and other sites (including but not limited to the large blood vessels of the abdomen and the veins of the lower extremities) combined with thrombocytopenia and with onset of symptoms approximately one to two weeks after vaccination. Most cases of thrombosis with thrombocytopenia reported following the Janssen COVID-19 Vaccine have occurred in females ages 18 through 49 years; some have been fatal. The clinical course of these events shares features with autoimmune heparin-induced thrombocytopenia. In individuals with suspected thrombosis with thrombocytopenia following the Janssen COVID-19 Vaccine, the use of heparin may be harmful and alternative treatments may be needed. Consultation with hematology specialists is strongly recommended.”

By May 7, 2021, there had been 28 cases of TTS and 3 deaths confirmed by the CDC to be related to the Johnson & Johnson/Janssen COVID-19 vaccine. TTS was also reported in men and in women between 50 and 60 years of age, in addition to women between the ages of 18 and 49 years.  According to the CDC, TTS occurred at a rate of 1 case per 250,000 doses of the vaccine. 

On December 16, 2021, the CDC gave a preferential recommendation for mRNA COVID-19 vaccines in lieu of the Johnson & Johnson/Janssen COVID-19 vaccine due to the risk of TTS.  According to the CDC, use of the Johnson & Johnson/Janssen vaccine was advised to be limited to persons who were unable to or unwilling to receive an mRNA COVID-19 vaccine, or when no other vaccine option was available. 

A study conducted by the Mayo Clinic and published in the Journal of the American Medical Association in November 2021 found that individuals who received the Janssen/Johnson & Johnson COVID-19 vaccine were 3.7 times more likely to develop cerebral venous sinus thrombosis (CVST) in comparison to the rates prior to the pandemic. Women were over five times more likely to develop CVST after vaccination when compared to pre-pandemic rates of the condition, with the highest rates in women 40-49 years of age, followed by women 30-39 years. Most cases of CVST were reported within 15 days of vaccination. Researchers did not have an answer on why women were more susceptible; however, autoantibody production or other risk factors that place a woman at increased risk of CVST were thought to play a role. 

On July 12, 2021, the FDA announced that it would be issuing a warning that the Johnson & Johnson/Janssen COVID-19 vaccine could trigger Guillain-Barré syndrome (GBS). By July 2021, health officials reported 100 cases of GBS following vaccination, with 95 considered serious and requiring hospitalization, and this data included one death. According to the FDA: 

“Although the available evidence suggests an association between the Janssen vaccine and increased risk of GBS, it is insufficient to establish a causal relationship….Importantly, the FDA has evaluated the available information for the Janssen COVID-19 Vaccine and continues to find the known and potential benefits clearly outweigh the known and potential risks.”

Per the CDC, rates of GBS within 21 days following the Johnson & Johnson/ Janssen COVID-19 vaccine were 21 times higher than after the Moderna or Pfizer/BioNTech mRNA COVID-19 vaccines. After 42 days following vaccination with the Johnson & Johnson/ Janssen COVID-19 vaccines, rates were 11 times higher than after the available mRNA COVID-19 vaccines. 

In early September 2021, the European Medicines Agency reported that its Pharmacovigilance Risk Assessment Committee (PRAC) was investigating a link between the Johnson & Johnson/Janssen COVID-19 vaccine and venous thromboembolism (blood clots in the veins). According to PRAC, in the initial clinical trials of the vaccine, a higher rate of venous thromboembolism was noted in the vaccine group when compared to the placebo group. Additional data collected from two larger clinical trials were expected to be submitted to PRAC in advance of vaccine marketing authorization, to determine whether the condition was linked to vaccination.   

The FDA updated the Johnson & Johnson/Janssen COVID-19 Vaccine Fact Sheet for Health Care Providers Administrating Vaccine on January 11, 2022 with information regarding the serious risk of immune thrombocytopenia (ITP) within 42 days of vaccination. ITP is a blood disorder that can cause excessive bruising and bleeding due to very low levels of platelets. 

Johnson & Johnson/Janssen COVID-19 Vaccine Production Concerns

On March 31, 2021, The New York Times reported that vaccine ingredients were mixed up by employees at an Emergent BioSolutions plant in Baltimore, resulting in up to 15 million ruined Johnson & Johnson vaccine doses. The mistake, which was determined by federal investigators to be the result of “human error”, was caught before any doses were released for distribution. The Baltimore plant was enlisted by the federal government in 2020 to manufacture vaccines developed by both Johnson & Johnson and AstraZeneca. While these vaccines use similar technologies, their ingredients and manufacturing processes are not interchangeable. According to The New York Times, in February 2021, one or more workers erred in the production process and this error was not discovered by Johnson & Johnson quality control checks for several days. 

This was not the first time that the Emergent BioSolutions Baltimore plant had been cited for errors. In April 2020, an FDA investigator had discovered that employees at the plant lacked adequate training, that testing protocols were not being followed, that records were not properly secured, and that policies to ensure that mix-ups or contaminations would not occur were found to be inadequate. Despite these safety issues, the plant was awarded $628 million by the U.S. government and also secured deals worth more than $740 million with AstraZeneca and Johnson & Johnson to manufacture COVID-19 vaccines for both companies at the Baltimore site. 

On April 20, 2021, the FDA cited the Baltimore Emergent BioSolutions plant for multiple quality control and sanitary issues, including their failure to adequately review and investigate the events that resulted in the manufacturing of 15 million botched Johnson & Johnson vaccine doses. Additionally, the FDA reported that they were not confident that previously released batches of the vaccines were not subject to cross-contamination. Unsanitary conditions at the plant included chipping paint from the walls in the hallways surrounding the manufacturing rooms, “brown residue” on walls, “black residue” and debris on the floor, and congested work areas. Plant employees were noted to be carrying unsealed bags containing medical waste and even “throwing unsealed bags of special medical waste into the service elevator accessing the warehouse corridor.” 

In November 2021, Emergent BioSolutions reported that it was no longer manufacturing COVID-19 vaccines for the U.S. Government. The decision to end the contract was related to manufacturing concerns at the Baltimore plant. The Baltimore facility, however, was reportedly continuing the manufacturing of the Janssen/ Johnson & Johnson COVID-19 vaccine for global distribution. The company’s actions during the pandemic were subjected to a congressional investigation and was reportedly involved in a lawsuit pertaining to concerns of insider trading among company executives. 

Johnson & Johnson/Janssen Booster Doses

A booster dose of Janssen/Johnson & Johnson vaccine was authorized by the FDA on October 20, 2021, for all individuals 18 years and older and was permitted to be administered at least two months following administration of the first dose.  The CDC, however, recommended mRNA COVID-19 vaccines over the Johnson & Johnson/Janssen COVID-19 vaccine due to the risk of TTS.  Immunocompromised individuals who received two doses of the Johnson & Johnson/Janssen COVID-19 vaccine were recommended to receive a third COVID-19 vaccine at least two months after the second vaccine dose. 

On September 1, 2022, the CDC voted to recommend use of either the Moderna or Pfizer-BioNTech booster dose in all persons 18 years and older who previously received the Johnson & Johnson/Janssen COVID-19 vaccine. This booster dose was recommended at least two months after the primary or latest booster dose. 

FDA revocation of the Johnson & Johnson/Janssen COVID-19 vaccine EUA

On June 1, 2023, the FDA revoked the EUA for Johnson & Johnson/Janssen COVID-19 vaccine. According to the FDA, Janssen BioTech had requested the voluntary withdrawal of its COVID-19 vaccine due to lack of demand for new lots of the vaccine, the expiration of last vaccine lots purchased by the U.S. federal government, and the decision by company officials to decline to update the vaccine to target new and emerging COVID-19 strains. 

Johnson & Johnson/Janssen COVID-19 Vaccine Profits

In January of 2022, Johnson & Johnson reported earnings of $2.4B from its COVID-19 vaccine in 2021. The company, however, reported weaker than expected earnings in 2022 and announced that it would no longer be including the vaccine’s revenue expectations in their projections. 

Select disease / vaccine